Medpace (NASDAQ:MEDP) Announces Quarterly Earnings Results, Beats Expectations By $0.61 EPS

Medpace (NASDAQ:MEDP) released its quarterly earnings results on Monday. The company reported $3.67 EPS for the quarter, topping analysts’ consensus estimates of $3.06 by $0.61, Zacks reports. The firm had revenue of $558.57 million during the quarter, compared to analysts’ expectations of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same period in the previous year, the company earned $3.20 EPS. Medpace updated its FY 2025 guidance to 12.260-13.040 EPS.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $288.99 on Tuesday. The company has a market cap of $8.74 billion, a PE ratio of 22.88, a P/E/G ratio of 3.81 and a beta of 1.46. The business has a 50-day simple moving average of $317.57 and a two-hundred day simple moving average of $332.88. Medpace has a fifty-two week low of $269.08 and a fifty-two week high of $459.77.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on MEDP shares. Truist Financial reduced their price target on Medpace from $347.00 to $333.00 and set a “hold” rating on the stock in a report on Thursday, April 10th. Mizuho lowered their price objective on shares of Medpace from $400.00 to $355.00 and set an “outperform” rating for the company in a research report on Wednesday, April 9th. Leerink Partnrs raised shares of Medpace to a “hold” rating in a research report on Monday, March 24th. Robert W. Baird increased their price objective on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Finally, Leerink Partners started coverage on Medpace in a research report on Monday, March 24th. They set a “market perform” rating and a $330.00 price target on the stock. Ten analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $357.50.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.